TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22872468
Drug: Oral calcium
Normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcium load (1 g)
Study: 22872468
Drug: Oral peptone
Normalized name: peptones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral peptone load with aluminum hydroxide (AH)
Study: 10997952
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (25 g CrH2O)
Study: 9075670
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg terlipressin
Study: 8566840
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg terlipressin
Study: 8368169
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of nebulized solution of non-bronchodilator (+) isoprenaline
Study: 3758469
Drug: HCT +
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HCT + AMI (50 mg/5 mg)
Study: 3758469
Drug: F +
Normalized name: Estroven Menopause Relief + Mood Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: F + TRI (40 mg/50 mg)
Study: 29722590
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 capsule (5,000 IU/day)
Study: 26684633
Drug: Intra-articular TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular TNF blockers
Study: 24857299
Drug: Tirofiban early
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirofiban early treatment group (administered routinely at ≥ 4 hours prior to angiography)
Study: 24857299
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (tirofiban provisional administered during or after angiography)
Study: 20059474
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review and counselling by a clinical pharmacist and clinical pharmacologist
Study: 20059474
Drug: Usual routine
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual routine medication review in the ward
Study: 20059474
Drug: Systematic medication
Normalized name: Integrase Inhibitors, antiinfectives for systematic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic medication review and counselling
Study: 12182234
Drug: Mud pack
Normalized name: Cream, Multi Ingredient Topical application Cream [3 ROSES FACIAL MUD PACK]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mud pack treatment
Study: 12182234
Drug: Thermal bath
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal bath treatment
Study: 7579091
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 400 mg and a daily dose of 200 mg/day for 9 days (Group 1)
Study: 7579091
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 200 mg and a maintenance dose of 100 mg/day for 9 days (Group 2)
Study: 7579091
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 100 mg and a maintenance dose of 50 mg/day for 9 days (Group 3)
Study: 7579091
Drug: Loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loading dose of 200 mg and then 100 mg after each of four dialysis sessions (Group 4)
Study: 1954179
Drug: Initial chemotherapy
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial chemotherapy followed by loco-regional treatment
Study: 6800046
Drug: Phenoxymethylpenicillin 800
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenoxymethylpenicillin 800 mg
Study: 6800046
Drug: Azidocillin 750
Normalized name: azidocillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azidocillin 750 mg
Study: 6800046
Drug: Antibiotics (Phenoxymethylpenicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (Phenoxymethylpenicillin and Azidocillin)
Study: 25635593
Drug: Norepinephrine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine 5 μg/ml
Study: 25635593
Drug: Phenylephrine 100
Normalized name: phenylephrine 100 mcg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine 100 μg/ml
Study: 21069355
Drug: Early feeding
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early feeding group (EFG) - oral liquid diet on the first postoperative day, advanced to regular diet within 24 hours as tolerated.
Study: 21069355
Drug: Traditional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional care group - nothing per orus until elimination of first flatus, then oral liquid diet followed by regular diet within 24 hours.
Study: 18362558
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream application
Study: 17413628
Drug: Cold application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold application and EMLA cream application
Study: 10802893
Drug: 0.625 mg
Normalized name: estrone 0.625 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg conjugated estrogens and 2.5 mg medroxyprogesterone acetate
Study: 8820551
Drug: Judicially monitored
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Judicially monitored mental health treatment
Study: 2860162
Drug: Povidone-iodine lubricating
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone-iodine lubricating gel (PVP-I)
Study: 31228090
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine
Study: 26340704
Drug: Insulin Detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin Detemir
Study: 25008853
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (500 mg daily)
Study: 17700424
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus GG (LGG) powder containing 60 million cells, twice daily for a minimum period of 7 days
Study: 11176329
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) alone
Study: 2254222
Drug: Clindamycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (300 mg qid for one day)
Study: 7357803
Drug: Propranolol 40
Normalized name: propranolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 40 mg every 8 hr for 1 wk
Study: 7357803
Drug: Acebutolol 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol 300 mg every 8 hr for 1 wk
Study: 28115517
Drug: Renal denervation
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal denervation plus stepped-care antihypertensive treatment
Study: 28115517
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (stepped-care treatment alone)
Study: 19757270
Drug: Sublingual misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sublingual misoprostol (2 tabs of 200 microg)
Study: 19757270
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (20 units at 10 cc/min)
Study: 2920499
Drug: Yohimbine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (4 mg t.i.d.)
Study: 20003300
Drug: Health coaching,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health coaching, home blood pressure monitoring, and home-titration of antihypertensive medications
Study: 17258358
Drug: Pneumococcal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal protein D conjugate vaccine
Study: 7766747
Drug: Lactulose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (30 g)
Study: 14658595
Drug: Colour Doppler
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colour Doppler ultrasound with contrast agents
Study: 7740055
Drug: Triazolam (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.125 or 0.25 mg per capsule)
Study: 7740055
Drug: Triazolam (0.0312-0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.0312-0.25 mg per capsule)
Study: 7740055
Drug: Experimenter-administered doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimenter-administered doses of triazolam
Study: 7023592
Drug: Physostigmine 0.375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.375 mg
Study: 7023592
Drug: Arecoline 4
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 4 mg
Study: 7023592
Drug: Physostigmine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.25 mg
Study: 7023592
Drug: Physostigmine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physostigmine 0.75 mg
Study: 7023592
Drug: Arecoline 2
Normalized name: bethanechol chloride Injectable Solution [Urecholine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arecoline 2 mg
Study: 31018173
Drug: Two-step stannous
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two-step stannous fluoride dentifrice and hydrogen peroxide whitening gel system, interactive oscillating-rotating electric toothbrush, and expanded polytetrafluoroethylene floss
Study: 26604072
Drug: Finerenone 1-40
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone 1-40 mg PEG solution
Study: 26604072
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg IR tablet
Study: 26604072
Drug: Finerenone 80
Normalized name: Finerenone
DrugBank: Finerenone (DB16165)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Finerenone 80 mg (eight × finerenone 10 mg IR tablets)
Study: 22408123
Drug: GH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH treatment (0.01 mg/kg per day for the first week, 0.02 mg/kg per day for the second week, and 0.03 mg/kg per day for the third week)
Study: 22408123
Drug: Pegvisomant treatment
Normalized name: Pegvisomant
DrugBank: Pegvisomant (DB00082)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegvisomant treatment (10 mg/day for the first week and 15 mg/day for the last two weeks)
Study: 18520979
Drug: Tetrabenazine (TBZ)
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrabenazine (TBZ) treatment withdrawal
Study: 18520979
Drug: Partial or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial or no withdrawal of TBZ treatment
Study: 23237982
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg daily
Study: 16135901
Drug: Efavirenz 800
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz 800 mg daily
Study: 16135901
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (600 mg and 800 mg)
Study: 7586338
Drug: Lovastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20 mg/d, titrated to 40 and then to 80 mg during the first 16 weeks)
Study: 7021057
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal dental treatment)
Study: 31755431
Drug: Oral propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propranolol 1 mg/kg/day titrated to 3 mg/kg/day over 1 week, continued for 6 months and tapered over 1 week
Study: 31755431
Drug: Intralesional propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional propranolol hydrochloride 1 mg/ml; 0.2 ml/cm, 3 doses 4-6 weeks apart
Study: 19427992
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab
Study: 26116264
Drug: Intravitreal anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal anti-VEGF medications (ranibizumab and bevacizumab)
Study: 21846439
Drug: Estrogen cream
Normalized name: ESTRIOL 4 mg in 85 g / ESTRADIOL 1 mg in 85 g TRANSDERMAL CREAM [BiEST 5.0 Estrogen Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen cream (3 g of vaginal cream containing 1.875 g of conjugated estrogens for six weeks)
Study: 21846439
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (comparable cream without estrogens for six weeks)
Study: 19210012
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Adherence and Depression (CBT-AD), 10 to 12 sessions
Study: 19210012
Drug: Enhanced Treatment
Normalized name: Thera-M Enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Treatment as Usual (ETAU), single-session intervention
Study: 1518670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group given narcotic-sedative premedication
Study: 6097117
Drug: Cefmenoxime (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefmenoxime (0.5 to 2.0 g every six hours)
Study: 6097117
Drug: Cefoxitin (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (0.5 to 2.0 g every six hours)
Study: 30927417
Drug: Ganirelix 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganirelix 0.25 mg/day
Study: 28687937
Drug: Combined nutraceutical
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined nutraceutical (red yeast rice 10 mg, phytosterols 800 mg, L-tyrosol 5 mg)
Study: 19555395
Drug: Telmisartan (40-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (40-80 mg/day)
Study: 19555395
Drug: Bisoprolol (5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (5-10 mg/day)
Study: 11371728
Drug: 2-deoxy-D-glucose (2-DG)
DrugBank: 2-deoxyglucose (DB08831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-deoxy-D-glucose (2-DG) infusion
Study: 8005128
Drug: Ramipril treatment
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril treatment for 12 weeks
Study: 2585534
Drug: 0.5 mg/m3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/m3 respirable activated carbon aerosol
Study: 1094748
Drug: Topically-applied buphenin
Normalized name: buphenine
DrugBank: Nylidrin (DB06152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically-applied buphenin (in a gel basis)
Study: 12372443
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (3.75 mg i.m. every 28 days for 3 months)
Study: 10674010
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 30 mg daily for 1 year
Study: 10674010
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles) + TAM
Study: 10674010
Drug: CMF (cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF (cyclophosphamide 600, methotrexate 40, 5‐fluorouracil 600 mg/m2 i.v. every 4 weeks, 9 cycles)
Study: 31937160
Drug: Rectal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rectal progesterone 200 mg daily until 36+6 weeks or spontaneous delivery
Study: 15991504
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in a similar manner
Study: 31680085
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment combined with benzbromarone
Study: 30672211
Drug: Pestle needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pestle needling therapy, applied once daily for 4 weeks.
Study: 30672211
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment and nursing for diabetes (Control group).
Study: 22679715
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (Bacillus licheniformis and Deanxit)
Study: 18046717
Drug: 72 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 72 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Study: 18046717
Drug: 48 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 48 weeks of peginterferon-alpha2b (1.5 mug/kg/week) and ribavirin (800-1400 mg/day)
Study: 10890258
Drug: Fosfomycin (3-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (3-g single dose)
Study: 10890258
Drug: Nitrofurantoin (100-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrofurantoin (100-mg capsules for 7 days)
Study: 7724749
Drug: L‐DOPA alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐DOPA alone (n = 16)
Study: 7724749
Drug: C‐11‐L‐DOPA and
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐11‐L‐DOPA and C‐11‐5‐HTP (n = 6)
Study: 2075773
Drug: Perioperative short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perioperative short-term antibiotic prophylaxis
Study: 2075773
Drug: Postoperative antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative antibiotic treatment
Study: 30787601
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg SBB‐PE
Study: 26997182
Drug: Prescription drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescription drug misuse trajectory
Study: 22381604
Drug: Immediate medical
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate medical treatment (oral mifepristone followed by vaginal misoprostol, n = 91)
Study: 22381604
Drug: Sequential management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential management (1 week of watchful waiting followed by medical treatment if necessary, n = 91)
Study: 22381604
Drug: Immediate medical
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate medical treatment
Study: 22381604
Drug: Sequential management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential management
Study: 12112798
Drug: salbutamol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: salbutamol plus BDP 200 microg bid by metered dose inhaler (MDI) with a spacer
Study: 1798317
Drug: Caffeine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (10 mg.kg‐1) taken immediately prior to exercise
Study: 26886503
Drug: Usual drug
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual drug education program (control group)
Study: 25046272
Drug: Subcutaneous MNX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous MNX (0.9 mg/kg)
Study: 17927497
Drug: Fish oil,
Normalized name: Fish Oil, oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil, 2 g tid plus placebo capsules bid (n = 12)
Study: 17927497
Drug: Fish oil,
Normalized name: Fish Oil, oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil, 2 g tid plus celecoxib 200 mg bid (n = 10)
Study: 11856592
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with bone marrow or stem cell support
Study: 11856592
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single agent chemotherapy (doxorubicin, epirubicin, ifosfamide)
Study: 8180354
Drug: Anticytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticytokine treatment
Study: 8180354
Drug: Antiprotease treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiprotease treatment
Study: 1819435
Drug: AIK-C vaccine
Normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIK-C vaccine at 4-5 months
Study: 1819435
Drug: Edmonston-Zagreb vaccine
Normalized name: measles virus vaccine live, Enders' attenuated Edmonston strain
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edmonston-Zagreb vaccine at 4-5 months
Study: 1819435
Drug: High-dose Schwarz
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Schwarz vaccine at 4-5 months
Study: 1819435
Drug: High-dose Edmonston-Zagreb
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose Edmonston-Zagreb vaccine for seropositive children
Study: 1819435
Drug: AIK-C vaccine
Normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIK-C vaccine for seropositive children
Study: 1819435
Drug: Schwarz vaccine
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz vaccine for seropositive children
Study: 1819435
Drug: AIK-C vaccine
Normalized name: Meningococcal polysaccharide vaccine group C
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIK-C vaccine at 8-10 months
Study: 1819435
Drug: Schwarz vaccine
Normalized name: measles virus vaccine live, attenuated Schwarz strain / mumps virus vaccine live, Jeryl Lynn strain / rubella virus vaccine live (Wistar RA 27-3 strain) Injection [Priorix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Schwarz vaccine at 8-10 months